vs
Side-by-side financial comparison of AIM ImmunoTech Inc. (AIM) and HALOZYME THERAPEUTICS, INC. (HALO). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $21.0K, roughly 21512.7× AIM ImmunoTech Inc.). HALOZYME THERAPEUTICS, INC. runs the higher net margin — -31.3% vs -19881.0%, a 19849.6% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs -53.3%). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs -27.5%).
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
AIM vs HALO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $451.8M |
| Net Profit | $-4.2M | $-141.6M |
| Gross Margin | — | 82.6% |
| Operating Margin | -14057.1% | -20.6% |
| Net Margin | -19881.0% | -31.3% |
| Revenue YoY | -53.3% | 51.6% |
| Net Profit YoY | 30.0% | -203.3% |
| EPS (diluted) | $-6.46 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | $451.8M | ||
| Q3 25 | $26.0K | $354.3M | ||
| Q2 25 | $25.0K | $325.7M | ||
| Q1 25 | $16.0K | $264.9M | ||
| Q4 24 | $45.0K | $298.0M | ||
| Q3 24 | $35.0K | $290.1M | ||
| Q2 24 | $50.0K | $231.4M | ||
| Q1 24 | $40.0K | $195.9M |
| Q4 25 | $-4.2M | $-141.6M | ||
| Q3 25 | $-3.3M | $175.2M | ||
| Q2 25 | $-2.8M | $165.2M | ||
| Q1 25 | $-3.7M | $118.1M | ||
| Q4 24 | $-6.0M | $137.0M | ||
| Q3 24 | $-3.7M | $137.0M | ||
| Q2 24 | $-1.8M | $93.2M | ||
| Q1 24 | $-5.8M | $76.8M |
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -14057.1% | -20.6% | ||
| Q3 25 | -9411.5% | 61.5% | ||
| Q2 25 | -10584.0% | 62.2% | ||
| Q1 25 | -22618.8% | 53.4% | ||
| Q4 24 | -13011.1% | 58.9% | ||
| Q3 24 | -12825.7% | 56.3% | ||
| Q2 24 | -7388.0% | 50.7% | ||
| Q1 24 | -14335.0% | 48.8% |
| Q4 25 | -19881.0% | -31.3% | ||
| Q3 25 | -12630.8% | 49.5% | ||
| Q2 25 | -11176.0% | 50.7% | ||
| Q1 25 | -23156.3% | 44.6% | ||
| Q4 24 | -13260.0% | 46.0% | ||
| Q3 24 | -10571.4% | 47.2% | ||
| Q2 24 | -3672.0% | 40.3% | ||
| Q1 24 | -14542.5% | 39.2% |
| Q4 25 | $-6.46 | $-1.13 | ||
| Q3 25 | $1.57 | $1.43 | ||
| Q2 25 | $-3.68 | $1.33 | ||
| Q1 25 | $-0.05 | $0.93 | ||
| Q4 24 | $-21.80 | $1.06 | ||
| Q3 24 | $-6.00 | $1.05 | ||
| Q2 24 | $-3.00 | $0.72 | ||
| Q1 24 | $-0.12 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $133.8M |
| Total DebtLower is stronger | $4.5M | $2.1B |
| Stockholders' EquityBook value | $-9.8M | $48.8M |
| Total Assets | $5.8M | $2.5B |
| Debt / EquityLower = less leverage | — | 43.89× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $133.8M | ||
| Q3 25 | $2.4M | $419.7M | ||
| Q2 25 | $835.0K | $61.9M | ||
| Q1 25 | $2.2M | $176.3M | ||
| Q4 24 | $4.0M | $115.8M | ||
| Q3 24 | $7.2M | $154.3M | ||
| Q2 24 | $10.1M | $187.9M | ||
| Q1 24 | $10.9M | $164.6M |
| Q4 25 | $4.5M | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $2.7M | $1.5B | ||
| Q1 25 | $2.4M | $1.5B | ||
| Q4 24 | $2.8M | $1.5B | ||
| Q3 24 | $3.3M | $1.5B | ||
| Q2 24 | $3.3M | $1.5B | ||
| Q1 24 | $3.3M | $1.5B |
| Q4 25 | $-9.8M | $48.8M | ||
| Q3 25 | $-6.1M | $503.9M | ||
| Q2 25 | $-6.5M | $332.7M | ||
| Q1 25 | $-3.9M | $482.3M | ||
| Q4 24 | $-1.3M | $363.8M | ||
| Q3 24 | $2.9M | $452.7M | ||
| Q2 24 | $6.1M | $289.4M | ||
| Q1 24 | $4.8M | $177.8M |
| Q4 25 | $5.8M | $2.5B | ||
| Q3 25 | $5.5M | $2.2B | ||
| Q2 25 | $4.1M | $2.1B | ||
| Q1 25 | $6.2M | $2.2B | ||
| Q4 24 | $8.6M | $2.1B | ||
| Q3 24 | $13.6M | $2.1B | ||
| Q2 24 | $15.7M | $2.0B | ||
| Q1 24 | $16.2M | $1.8B |
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | 1.13× | 3.32× | ||
| Q2 24 | 0.54× | 5.19× | ||
| Q1 24 | 0.69× | 8.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $219.0M |
| Free Cash FlowOCF − Capex | — | $217.6M |
| FCF MarginFCF / Revenue | — | 48.2% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $644.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.0M | $219.0M | ||
| Q3 25 | $-5.1M | $178.6M | ||
| Q2 25 | $-1.5M | $99.7M | ||
| Q1 25 | $-2.4M | $154.2M | ||
| Q4 24 | $-4.0M | $178.5M | ||
| Q3 24 | $-3.1M | $115.4M | ||
| Q2 24 | $-3.0M | $55.8M | ||
| Q1 24 | $-4.8M | $129.4M |
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $125.9M |
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 64.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIM
Segment breakdown not available.
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
